FDA Introduces Spectral Library - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

FDA Introduces Spectral Library
FDA, in cooperation with IPEC, is building a spectral library of excipients to detect improper ingredients within a drug product on site.


Pharmaceutical Technology
Volume 35, Issue 7, pp. 67-70

Will the library be available to everyone?

The agency does not plan to share the library at this time. If industry and the agency see value in sharing the library in the future, FDA will conform to any provisions in the MTAs.

Will others be able to contribute to the spectral library?

FDA prefers to obtain excipients directly from manufacturers or distributors to be certain of their identity and provenance of the manufacturer and/or manufacturing site to minimize the possibility that a contaminated or subpar quality excipient is included in the library. As far as contributing spectral entries into the spectral database, FDA will not be accepting spectra.

How will the materials be used and/or evaluated?

Both Raman and NIR spectra of the excipients received will be generated without further testing or qualification of the material. As the scope of this effort is to establish a spectral library database, FDA does not plan to perform quality testing.

Would there be a time factor for the samples (i.e., would the manufacturer need to send samples every year)?

For most samples, this step would not be required. However, manufacturers could send new samples if they felt a process or raw material change could affect the spectrum of their material.

Acknowledgments

John Kauffman, Jason Rodriguez, Steve Wolfgang, William Busch, Karen Richardson, Chris Moreton, Patrick Rice, Ken Crook, Chi-san Wu, Asenicion Koenig, Carl Perini, Bret Clark, Justin Denault, Irwin Silverstein, Priscilla Zawislak, Art Falk, Dale Carter, Dave Schoneker, Alan Potts.

Lucinda F. Buhse is director of the Division of Pharmaceutical Analysis in FDA's Office of Testing and Research. Philip H. Merrell is a subcommittee chair at the International Pharmaceutical Excipients Council of the Americas and a technical market manager at Jost Chemical, tel. 314.428.4300.

References

1. D.M. Autor, FDA, presentation given at DCAT Week, New York, Mar. 18, 2009.

2. J. Taylor, III, FDA, presentation given at Pew Health Group Conference, Washington DC, Mar. 14, 2011.

3. J.F. Kauffman et al., Amer. Pharm. Rev. 13, 58–64 (2010) .

4. S. Arzhantsev, X. Li, and JF Kauffman, Analyt. Chem. 83, 1061–1068 (2011).

5. C.M. Gryniewicz-Ruzicka et al., Appl. Spectrosc. 65, 334–341 (2011).

6. J.D. Dunn et al., Jrnl. of Pharm. Sci. 54, 469–474 (2011).

7. X. Li, S. Arzhantsev, J.F. Kauffman, and J.A. Spencer, Jrnl. of Pharm. and Biomed. Anal. 54, 1001–1006 (2011).

8. J.F. Kauffman, L.F. Buhse, and J.D. Rodriguez, Amer. Pharm. Rev., in Press (2011).

9. J.D. Rodriguez, B.J. Westenberger, L.F. Buhse, and J.F. Kauffman, The Analyst, in revision (2011).

10. J.D. Rodriguez, B.J. Westenberger, L.F. Buhse, and J.F. Kauffman, Analyt. Chem., 83, 4061–4067 (2011).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
30%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
8%
All of the above.
45%
No government involvement in patient treatment or drug development.
8%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
Source: Pharmaceutical Technology,
Click here